Novel 1,3-diarylpyrazole acrylamides: Synthesis, antiplatelet activity screening, and in silico evaluation studies

Medicinal Chemistry Research

Volumn 22, Issue 12, 2013, Pages 5922-5933

  Baytas, Sultan Nacak ^a   Inceler, Nazan ^a   Ozkan, Yesim ^a   Unlu, Serdar ^a,b   Fethi Sahin, M ^a  

^a GAZI UNIVERSITY   (Turkey)

^b Department of Pharmaceutical Research and Development   (Turkey)

Author keywords

1,3 Diarylpyrazoles; Acryl amides; Antiplatelet activity; Arachidonic acid; Collagen

Indexed keywords

(2E) N (4 METHOXYBENZYL) 3 (1 PHENYL 3 (PYRIDIN 4 YL) 1H PYRAZOL 4 YL)ACRYLAMIDE; (2E) N BENZYL 3 (1 PHENYL 3 (PYRIDIN 4 YL) 1H PYRAZOL 4YL)ACRYLAMIDE; (2E) N CYCLOHEXYL 3 (1 PHENYL 3 (PYRIDIN 4 YL) 1H PYRAZOL 4 YL)ACRYLAMIDE; (2E) N CYCLOPROPYL 3 (1 PHENYL 3 (PYRIDIN 4 YL) 1H PYRAZOL 4 YL)ACRYLAMIDE; (E) 3 [1 PHENYL 3 (PYRIDIN 4 YL) 1H PYRAZOL 4 YL]ACRYLAMIDE; (E) 3 [1 PHENYL 3 (PYRIDIN 4 YL) 1H PYRAZOL 4 YL]ACRYLIC ACID; 1 (2 ETHOXYPHENYL) 4 [(2E) 3 (1 PHENYL 3 (PYRIDIN 4 YL) 1H PYRAZOL 4 YL)PROP 2 ENOYL]PIPERAZINE; 1 (2 FUROYL) 4 [(2E) 3 (1 PHENYL 3 (PYRIDIN 4 YL) 1H PYRAZOL 4 YL)PROP 2 ENOYL]PIPERAZINE; 1 (2 METHOXYPHENYL) 4 [(2E) 3 [1 PHENYL 3 (PYRIDIN 4 YL) 1H PYRAZOL 4 YL]PROP 2 ENOYL]PIPERAZINE; 1 (2,3 DIMETHYLPHENYL) 4 [(2E) 3 [1 PHENYL 3 (PYRIDIN 4 YL)1H PYRAZOL 4 YL]PROP 2 ENOYL]PIPERAZINE; 1 (3 CHLOROPHENYL) 4 [(2E) 3 [1 PHENYL 3 (PYRIDIN 4 YL) 1H PYRAZOL 4 YL]PROP 2 ENOYL]PIPERAZINE; 1 (4 CHLOROPHENYL) 4 [(2E) 3 [1 PHENYL 3 (PYRIDIN 4 YL) 1H PYRAZOL 4 YL]PROP 2 ENOYL]PIPERAZINE; 1 (4 METHYLPHENYL) 4 [(2E) 3 [1 PHENYL 3 (PYRIDIN 4 YL) 1H PYRAZOL 4 YL]PROP 2 ENOYL]PIPERAZINE; 1 [(2E) 3 (1 PHENYL 3 (PYRIDIN 4 YL) 1H PYRAZOL 4 YL)PROP 2 ENOYL] 4 (2,3,4 TRIMETHOXYBENZYL)PIPERAZINE; 1 [(2E) 3 (1 PHENYL 3 (PYRIDIN 4 YL) 1H PYRAZOL 4 YL)PROP 2 ENOYL] 4 (TETRAHYDROFURAN 2 YL CARBONYL)PIPERAZINE; 1 [(2E) 3 (1 PHENYL 3 (PYRIDIN 4 YL) 1H PYRAZOL 4 YL)PROP 2 ENOYL] 4 PYRIDIN 4 YLPIPERAZINE; 1 [(2E) 3 [1 PHENYL 3 (PYRIDIN 4 YL) 1H PYRAZOL 4 YL]PROP 2 ENOYL] 4 [3 (TRIFLUOROMETHYL)PHENYL]; 1 PHENYL 3 (PYRIDIN 4 YL) 1H PYRAZOLE 4 CARBALDEHYDE; 1 PHENYL 4 [(2E) 3 [1 PHENYL 3 (PYRIDIN 4 YL) 1H PYRAZOL 4 YL]PROP 2 ENOYL]PIPERAZINE; 2 (2 {4 [(2E) 3 (1 PHENYL 3 (PYRIDIN 4 YL) 1H PYRAZOL 4 YL)PROP 2 ENOYL]PIPERAZINE 1 YL}ETHOXY)ETHANOL; 2 {4 [(2E) 3 (1 PHENYL 3 (PYRIDIN 4 YL) 1H PYRAZOL 4 YL)PROP 2 ENOYL]PIPERAZINE 1 YL}PYRIMIDINE; 4 (1 (2 PHENYLHYDRAZONO)ETHYL)PYRIDINE; 4 [(2E) 3 (1 PHENYL 3 (PYRIDIN 4 YL) 1H PYRAZOL 4 YL)PROP 2 ENOYL]MORPHOLINE; 4 {4 [(1E) 3 (4 BENZYLPIPERIDIN 1 YL) 3 OXOPROP 1 EN 1 YL] 1 PHENYL 1H PYRAZOL 3 YL}PYRIDINE; 4 {4 [(1E) 3 OXO 3 (PIPERIDIN 1 YL)PROP 1 EN 1 YL] 1 PHENYL 1H PYRAZOL 3 YL}PYRIDINE; ACRYLAMIDE DERIVATIVE; ANTITHROMBOCYTIC AGENT; ARACHIDONIC ACID; UNCLASSIFIED DRUG;

ARTICLE; CARBON NUCLEAR MAGNETIC RESONANCE; COMPUTER MODEL; DRUG SCREENING; DRUG SYNTHESIS; HUMAN; IC 50; THROMBOCYTE ACTIVATION; THROMBOCYTE AGGREGATION;

EID: 84886094540     PISSN: 10542523     EISSN: 15548120     Source Type: Journal    
DOI: 10.1007/s00044-013-0580-x     Document Type: Article

References (34)

1. Algul O, Meric A, Polat S, Yuksek ND, Serin MS (2009) Comparative studies on conventional and microwave-assisted synthesis of a series of 2,4-di and 2,3,4-trisubstituted benzimidazo[1,2-a]pyrimidines and their antimicrobial activities. Cent Eur J Chem 7:337-342
2. Arita H, Hansaki K (1989) Thromboxane A2: its generation and role in platelet activation. Prog Lipid Res 28:273-301
3. Badadhe PV, Chavan NM, Ghotekar S, Mandhane PG, Joshi RS, Gill CH (2011) Synthesis, characterization, and biological screening of some novel thiazolidin-4-one and alpha-aminophosphonate derivatives. Phosphorus Sulfur and Silicon Relat Elem 186:2021-2032
4. Baytas S, Turan Dural NN, Özkan Y, Simsek HB, Gürsel T, Ünlü S (2012) Synthesis, anti-inflammatory, antiplatelet and in silico evaluations of (E)-3-(3-(2,3-dihydro-3-methyl-2-oxo-3H-benzoxazole-6-yl)-1- phenyl-1H-pyrazole-4-yl)acrylamides. Turk J Chem 36:367-382
5. Bennett JS (2001) Novel platelet inhibitors. Annu Rev Med 52:161-184
6. Berger PB (1999) The thienopyridines in coronary artery disease. Curr Cardiol Rep 1:192-198
7. Born G, Cross M (1963) The aggregation of blood platelet. J Physiol 168:178-195
8. Brueggemeier RW, Hackett JC, Diaz-Cruz ES (2005) Aromatase inhibitors in the treatment of breast cancer. Endocr Rev 26:331-345
9. Chu CC, Teague PC (1958) 4-Pyridylhydantoins. J Org Chem 23:1578
10. Davis MJ, Thomas AC (1985) Plaque fissuring-the cause of acute myocardial infarction, sudden ischaemic death, and crescendo angina. Br Heart J 53:363-373
11. De Leval X, Hanson J, David JL, Masereel B, Pirotte B, Dogne JM (2004) New developments on thromboxane and prostacyclin modulators. Part II: prostacyclin modulators. Curr Med Chem 11:1243-1252
12. Ertl P, Rohde B, Selzer P (2000) Fast calculation of molecular polar surface area as a sum of fragment-based contributions and its application to the prediction of drug transport properties. J Med Chem 43:3714-3717
13. Escalante J, Diaz-Coutino FD (2009) Synthesis of c-nitro aliphaticmethyl esters via Michael additions promoted by microwave irradiation. Molecules 14:1595-1604
14. Fuster V, Badimon L, Badimon JJ, Chesebro JH (1992) The pathogenesis of coronary artery disease and the acute coronary syndromes (1). N Engl J Med 326:242-250
15. http://www.molinspiration.com/cgi-bin/properties
16. http://www.organic-chemistry.org/prog/peo
17. Jackson SP, Schoenwaelder SM (2003) Antiplatelet therapy: in search of the 'magic bullet'. Nat Rev Drug Discov 2:775-789
18. Jyothi C, Rai SN, Kalluraya B (2007) Environmentally benign synthesis of sydnone containing 1,3,4-thiadiazines under microwave and solvent free conditions. J Chem Sci 119:299-302
19. Kalluraya B, Rao JN, Sujith KV (2008) Microwave assisted one-pot synthesis of some 2,5-disubstituted 1,3,4-oxadiazoles. Indian J Heterocycl Chem 17:359-362
20. Lipinski CA, Lombardo F, Dominy BW, Feeney PJ (2001) Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv Drug Deliv Rev 46:3-26
21. Lizuka K, Akahane K, Momose D, Nakazawa M (1981) Highly selective inhibitors of thromboxane synthetase. 1 Imidazole derivatives. J Med Chem 24:1139-1148
22. Loo MH, Egan D, Vaughan ED, Marion D, Felsen D, Weisman S (1987) The effect of the thromboxane A2 synthesis inhibitor OKY-046 on renal function in rabbits following release of unilateral ureteral obstruction. J Urol 137:571-576
23. Mason PJ, Jacobs AK, Freedman JE (2005) Aspirin resistance and atherothrombotic disease. J Am Coll Cardiol 46:986-993
24. McKee SA, Sane DC, Deliargyris EN (2002) Aspirin resistance in cardiovascular disease: a review of prevalence, mechanisms, and clinical significance. Thromb Haemost 88:711-715
25. Needleman P, Turk J, Jakschik BA, Morrison AR, Morrison AR, Lefkowith JB (1986) Arachidonic acid metabolism. Annu Rev Biochem 55:69-102
26. Patrignani P (2003) Aspirin insensitive eicosanoid biosynthesis in cardiovascular disease. Thromb Res 110:281-286
27. Schros K (1995) Antiplatelet drugs: a comparative review. Drugs 50:7-28
28. Silveira IAFB, Paulo LG, Miranda ALP, Rocha SO, Freita ACC, Barreiro EJ (1993) New pyrazolylhydrazone derivatives as inhibitors of platelet aggregation. J Pharm Pharmacol 45:646-649
29. Stahl E (1969) Thin-layer Chromatography. Springer, New York
30. Storey F (2001) The P2Y12 receptor as a therapeutic target in cardiovascular disease. Platelets 12:197-209
31. Tanouchi T, Kawamura M, Ohyama I, Kajiwara I, Iguchi Y, Okada T, Miyamoto T, Taniguchi K, Hayashi M, Lizuka K, Nakazawa M (1981) Highly selective inhibitors of thromboxane synthetase. 2. Pyridine derivatives. J Med Chem 24:1149-1155
32. Tetko IV (2005) Computing chemistry on the web. Drug Discov Today 10:1497-1500
33. Trip MD, Cats VM, Capelle FJL, Vreeken J (1990) Platelet hyperreactivity and prognosis in survivors of myocardial infarction. N Engl J Med 322:1549-1554
34. Yusuf S, Reddy S, Ounpuu S, Anand S (2001) Global burden of cardiovascular diseases: part I: general considerations, the epidemiologic transition, risk factors, and impact of urbanization. Circulation 104:2746-2753